Login to Your Account

In The Clinic NEWS

With a possible fix for compliance and side-effect issues in Alzheimer's disease, Corium International Inc. drew attention from Wall Street by way of positive top-line phase I data.

Differences in dosing, duration and the disability of patients likely led to Pfizer Inc.'s phase II fizzle with its 5-hydroxytryptamine6 serotonin receptor antagonist in Alzheimer's disease.

Exelixis Inc. added increased overall survival vs. Afinitor to the list of benefits provided by cabozantinib for second-line renal cell carcinoma patients, providing what president and CEO Michael Morrissey told BioWorld Today was “the missing piece of the puzzle in terms of the full cabozantinib second line RCC story.”

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: